Law360, New York (August 02, 2012, 9:46 PM ET) -- Johnson & Johnson has settled claims brought by the U.S. Department of Justice and several states that it illegally marketed its antipsychotic drug Risperdal, as well as False Claims Act and Medicaid-related allegations, according to a securities filing issued Thursday.
The agreement will resolve claims made in the Eastern District of Pennsylvania surrounding Johnson & Johnson’s marketing of Risperdal and schizophrenia drug Invega, according to the U.S. Securities and Exchange Commission filing. It will also settle suits in California over its marketing of heart failure drug...
J&J Settles Risperdal Marketing Claims From DOJ, States
To view the full article, take a free trial now.
